Biopharmaceutical buffer solutions are water-based preparations that help to maintain and stabilize the pH of solutions. There are various biopharma buffer solutions used for different applications such as cell disruption, downstream processing, filtration, and filling. Some common biopharma buffer solutions include Tris buffer, Phosphate buffer saline, Citrate buffer, and Histidine buffer. These buffer solutions play a vital role in purification, separation, stabilization, and transportation of biologics. Growing production of biosimilars is driving the demand for biopharma buffer solutions. With ample patent expiries of blockbuster biologics and rising healthcare costs, biosimilars production is expected to surge in the coming years.
The global Biopharma Buffer Market is estimated to be valued at US$ 3.68 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
Growing biosimilars production and rising demand for single-use systems: Growing production of biosimilars across the globe is a major driver fueling the demand for biopharma buffer solutions. The patent expiration of several blockbuster biologics in the past decade has opened significant opportunities for biosimilars. Additionally, rising adoption of single-use technologies and shift towards continuous bioprocessing is further driving the biopharma buffer market growth. Single-use systems require buffer solutions in small volumes compared to conventional stainless-steel bioreactors, thereby propelling market growth.
Segment Analysis
The biopharma buffer market can be segmented into three categories: biological buffer, chemical buffer, and physiological buffer. The biological buffer segment dominates the market and accounts for over 35% share. It is dominating as biological buffers are created from natural sources like proteins and are considered safer options, having fewer side effects, for applications involving tissues or cells.
PEST Analysis
Political: Regulations around pharmaceutical buffer manufacturing and supply is stringent. Harmonization of regulations can boost cross-border trade.
Economic: Growth in pharma and biotech industries is driving demand for buffers. However, pricing pressure on manufacturers impacts profits.
Social: Rising incidence of diseases and an aging population is increasing healthcare needs. This boosts buffer demand as they are essential in research, manufacturing and medical applications.
Technological: Advancements in buffer formulation, stability testing and storage conditions help develop safer and effective products. Digital tools aid efficient manufacturing and quality control.
Key Takeaways
The global biopharma buffer market share is expected to witness high growth over the forecast period aided by factors such as the expanding biopharmaceutical industry, advancements in drug development, and increasing research activities. The global Biopharma Buffer Market is estimated to be valued at US$ 3.68 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030.
Regional analysis: North America is the largest as well as the fastest growing regional market. This is attributed to presence of major pharma companies and high healthcare spending. Another fast growing region is Asia Pacific led by China and India where pharmaceutical manufacturing is booming.
Key players: Key players operating in the biopharma buffer market are Digital Medics Pty. Ltd., Emperra GmbH E-Health Technologies, and Merck KGaA. These companies have established positions in buffer manufacturing and supply aided by strong R&D capabilities and global distribution networks.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it